ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer
暂无分享,去创建一个
R. Govindan | G. Oxnard | D E Gerber | G R Oxnard | R Govindan | D. Gerber | GR Oxnard | David E. Gerber
[1] C. Dooms,et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[3] D. Costa,et al. Management and future directions in non-small cell lung cancer with known activating mutations. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[4] R. Marks,et al. Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] Richard J Stephens,et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.